Home/Orphelia Pharma/Hugues Bienaymé

HB

Hugues Bienaymé

General Manager and Chief Scientific Officer

Orphelia Pharma

Therapeutic Areas

Neurology Oncology Rare Diseases Pediatrics

Orphelia Pharma Pipeline

Drug	Indication	Phase
Kigabeq®	Tuberous Sclerosis Complex (TSC) with Subependymal Giant Cell Astrocytoma (SEGA)	Approved
Kizfizo®	Pediatric brain tumors	Under Review

Leadership Team at Orphelia Pharma

Gilles Alberici

Executive Chairman

Chief Pharmaceutical Affairs Officer

Jérémy Bastid

Chief Development Officer, Interim Chief Medical Officer

Caroline Lemarchand

Chief Pharmaceutical Development Officer

Séverine Martin

Project Management and Supply Chain Manager

View full Orphelia Pharma profile